Study of Blood Biomarkers to Predict Resistance to Androgen Receptor Inhibitors in Men With Metastatic Castration-Resistant Prostate Cancer

What this Trial Is About

Researchers are studying men with metastatic castration resistant prostate cancer mCRPC to see if certain genes or proteins found in circulating tumor cells CTCs can predict how well patients respond to hormonal therapies. The study aims to compare biomarkers from patients who respond well to treatment with those who do not, helping to understand resistance to androgen receptor inhibitors. This observational study focuses on men receiving standard care for their advanced prostate cancer. Men with progressive mCRPC starting standard treatment with second-generation androgen receptor inhibitors, such as enzalutamide or abiraterone acetate, will have blood samples collected at the start of treatment, after 12 weeks, and when their disease progresses. Researchers will analyze circulating tumor cells and other biomarkers over time to evaluate resistance to therapy. Participants will also provide an archival tumor biopsy sample for comparison. During the study, participants will undergo regular blood draws to assess biomarkers related to treatment response. Researchers will monitor progression-free survival, overall survival, PSA decline, soft tissue response, and therapy duration up to three years. The study involves close follow-up to observe molecular changes in circulating tumor cells during treatment progression, helping to advance understanding of prostate cancer resistance.

ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials